Fresh Tracks Therapeutics (FRTX) Competitors $0.72 0.00 (0.00%) (As of 12:19 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends FRTX vs. MRNS, CARA, TENX, SYBX, APRE, MTEX, INAB, TXMD, NERV, and AKTXShould you be buying Fresh Tracks Therapeutics stock or one of its competitors? The main competitors of Fresh Tracks Therapeutics include Marinus Pharmaceuticals (MRNS), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Synlogic (SYBX), Aprea Therapeutics (APRE), Mannatech (MTEX), IN8bio (INAB), TherapeuticsMD (TXMD), Minerva Neurosciences (NERV), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Fresh Tracks Therapeutics vs. Marinus Pharmaceuticals Cara Therapeutics Tenax Therapeutics Synlogic Aprea Therapeutics Mannatech IN8bio TherapeuticsMD Minerva Neurosciences Akari Therapeutics Fresh Tracks Therapeutics (NASDAQ:FRTX) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Does the MarketBeat Community prefer FRTX or MRNS? Marinus Pharmaceuticals received 437 more outperform votes than Fresh Tracks Therapeutics when rated by MarketBeat users. Likewise, 67.96% of users gave Marinus Pharmaceuticals an outperform vote while only 0.00% of users gave Fresh Tracks Therapeutics an outperform vote. CompanyUnderperformOutperformFresh Tracks TherapeuticsOutperform VotesNo VotesUnderperform Votes1100.00% Marinus PharmaceuticalsOutperform Votes43767.96% Underperform Votes20632.04% Does the media refer more to FRTX or MRNS? In the previous week, Marinus Pharmaceuticals had 8 more articles in the media than Fresh Tracks Therapeutics. MarketBeat recorded 8 mentions for Marinus Pharmaceuticals and 0 mentions for Fresh Tracks Therapeutics. Marinus Pharmaceuticals' average media sentiment score of 0.34 beat Fresh Tracks Therapeutics' score of 0.00 indicating that Marinus Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Fresh Tracks Therapeutics Neutral Marinus Pharmaceuticals Neutral Do insiders and institutionals have more ownership in FRTX or MRNS? 25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate FRTX or MRNS? Marinus Pharmaceuticals has a consensus price target of $4.79, suggesting a potential upside of 1,451.29%. Given Marinus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than Fresh Tracks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fresh Tracks Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Marinus Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36 Is FRTX or MRNS more profitable? Fresh Tracks Therapeutics has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. Fresh Tracks Therapeutics' return on equity of 0.00% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Fresh Tracks TherapeuticsN/A N/A N/A Marinus Pharmaceuticals -446.48%-7,831.35%-120.74% Which has more volatility and risk, FRTX or MRNS? Fresh Tracks Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Which has higher earnings and valuation, FRTX or MRNS? Fresh Tracks Therapeutics has higher earnings, but lower revenue than Marinus Pharmaceuticals. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFresh Tracks Therapeutics$8.01M0.53-$5.69M-$1.41-0.51Marinus Pharmaceuticals$30.99M0.55-$141.40M-$2.47-0.12 SummaryMarinus Pharmaceuticals beats Fresh Tracks Therapeutics on 14 of the 19 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Fresh Tracks Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FRTX vs. The Competition Export to ExcelMetricFresh Tracks TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.27M$2.97B$5.10B$8.84BDividend YieldN/A1.91%5.04%4.07%P/E Ratio-0.5119.5495.6214.26Price / Sales0.53283.311,217.1987.73Price / CashN/A169.3839.5936.27Price / Book0.434.356.946.36Net Income-$5.69M-$41.63M$118.89M$225.56M7 Day Performance0.70%-4.44%-1.33%-0.10%1 Month Performance0.70%-6.01%-3.17%2.02%1 Year Performance-9.49%26.52%32.49%27.87% Fresh Tracks Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FRTXFresh Tracks TherapeuticsN/A$0.72flatN/A-9.5%$4.27M$8.01M-0.5120MRNSMarinus Pharmaceuticals4.4503 of 5 stars$0.31-0.2%$4.79+1,451.3%-95.0%$17.03M$30.99M-0.13110Analyst ForecastAnalyst RevisionGap DownCARACara Therapeutics3.7192 of 5 stars$0.31+0.9%$2.32+654.2%-71.2%$16.88M$20.97M-0.1855Analyst ForecastTENXTenax Therapeutics2.7706 of 5 stars$4.81+0.8%$16.00+232.6%-83.5%$16.40MN/A0.009Analyst RevisionNews CoveragePositive NewsSYBXSynlogic2.7524 of 5 stars$1.40-3.1%$30.00+2,042.9%-30.5%$16.38M$3.37M-0.356Positive NewsAPREAprea Therapeutics3.3831 of 5 stars$2.92-3.0%$15.50+430.8%-22.4%$15.86M$580,000.000.007Analyst ForecastAnalyst RevisionGap DownMTEXMannatech0.936 of 5 stars$8.40+4.3%N/A-15.5%$15.79M$131.96M0.00250Analyst ForecastGap UpHigh Trading VolumeINABIN8bio2.7455 of 5 stars$0.34+4.2%$7.75+2,213.4%-62.8%$15.68MN/A0.0020TXMDTherapeuticsMD0.6657 of 5 stars$1.34flatN/A-54.1%$15.45M$1.30M0.00420Analyst ForecastNERVMinerva Neurosciences2.3494 of 5 stars$2.21+4.2%$5.00+126.2%-57.1%$15.45MN/A-4.829Analyst ForecastAKTXAkari TherapeuticsN/A$1.24-15.6%N/A-55.0%$15.07MN/A0.009Analyst ForecastNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Marinus Pharmaceuticals Alternatives Cara Therapeutics Alternatives Tenax Therapeutics Alternatives Synlogic Alternatives Aprea Therapeutics Alternatives Mannatech Alternatives IN8bio Alternatives TherapeuticsMD Alternatives Minerva Neurosciences Alternatives Akari Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FRTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fresh Tracks Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fresh Tracks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
